Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density
- Sponsor
- Havah Therapeutics Pty Ltd
- Study ID
- NCT03264651
- Phase
- PHASE1
- Status
- Completed
Conditions
- Mammographic Density
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- enobosarm — DRUGOral combination therapy of enobosarm and anastrozole
Study Details
To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.
Key Dates
- Start date
- Feb 1, 2017
- Status verified
- Feb 2018
- Primary completion
- Mar 21, 2018
- Completion
- Mar 21, 2018
Study Design
- Enrollment
- 9 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: oral enobosarm and anastrozole9 mg of oral enbosarm and 1 mg of anastrozole daily
Primary Outcome Measure
Mammographic breast density [ Time Frame: 12 months ]